Search





Search





Markets
/
Stocks
/
cgem
/

Cullinan Therapeutics Inc

CGEM

Add to Watchlist

16.500USD

-1.020-5.82%

Close 07-31 16:00（ET）Quotes delayed by 15 min

1.01BMarket Cap

LossP/E TTM

Cullinan Therapeutics Inc

16.500

-1.020-5.82%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

CGEM Cash Flow Statement

You can access the annual and quarterly cash flow statements of Cullinan Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2020Q3

FY2019Q4

FY2019Q3

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-6.70%-46.05M

-4.05%-38.11M

-8.02%-36.88M

-58.74%-57.61M

-12.83%-43.16M

-102.01%-36.63M

0.01%-34.14M

-17.05%-36.29M

25.00%-38.25M

27.43%-18.13M

37.19%-34.14M

-21.97%-31.01M

-132.78%-51.00M

-64.68%-24.98M

-415.15%-54.35M

-56.95%-25.42M

-1346.07%-21.91M

-60.78%-15.17M

-16.32%-10.55M

---16.20M

---1.52M

-93.80%-9.44M

-54.61%-9.07M

---4.87M

---5.87M

Net income from continuing operations

-2.39%-49.66M

-6.43%-50.71M

-24.78%-50.61M

-66.69%-70.06M

-29.89%-48.50M

-86.39%-47.65M

-3.51%-40.56M

-30.47%-42.03M

35.78%-37.34M

5.63%-25.56M

-57.42%-39.18M

-118.51%-32.21M

-350.99%-58.14M

20.81%-27.09M

-36.32%-24.89M

1158.85%174.06M

-1008.53%-12.89M

-17.52%-34.21M

-61.38%-18.26M

---16.44M

--1.42M

-515.22%-29.11M

-65.19%-11.31M

---4.73M

---6.85M

Operating gains losses

3.95%79.00K

2.60%79.00K

3.95%79.00K

0.00%77.00K

0.00%76.00K

0.00%77.00K

-85.38%76.00K

-4.94%77.00K

5.56%76.00K

30.51%77.00K

5677.78%520.00K

575.00%81.00K

453.85%72.00K

391.67%59.00K

-30.77%9.00K

-7.69%12.00K

-13.33%13.00K

-20.00%12.00K

-13.33%13.00K

--13.00K

--15.00K

-11.76%15.00K

-6.25%15.00K

--17.00K

--16.00K

Deferred tax

----

100.00%0.00

----

--19.57M

---19.57M

----

Other non-cash items

66.38%-777.00K

73.48%-931.00K

72.44%-1.36M

54.20%-1.71M

30.10%-2.31M

-0.49%-3.51M

-63.31%-4.93M

-73.66%-3.73M

-141.84%-3.31M

-857.26%-3.49M

-2021.66%-3.02M

-330.65%-2.15M

-244.50%-1.37M

-132.44%-365.00K

-83.05%157.00K

5.08%930.00K

313.10%946.00K

348.21%1.13M

1.65%926.00K

--885.00K

--229.00K

--251.00K

--911.00K

--0.00

Change in working capital

-84.16%-3.30M

27.44%6.14M

201.03%5.54M

464.81%4.19M

69.63%-1.79M

45.65%4.82M

1117.68%1.84M

75.30%-1.15M

-600.34%-5.90M

166.05%3.31M

99.48%-181.00K

-109.67%-4.65M

-61.03%1.18M

-187.10%-5.01M

-1678.39%-34.91M

1097.37%48.07M

145.29%3.03M

28.02%5.75M

67.96%2.21M

---4.82M

---6.69M

3076.16%4.49M

36.34%1.32M

---151.00K

--966.00K

-Change in prepaid expenses

-138.00%-662.00K

151.38%840.00K

-40.62%798.00K

235.69%3.52M

323.84%1.74M

50.36%-1.64M

135.27%1.34M

-235.28%-2.59M

154.44%411.00K

-428.73%-3.29M

-801.84%-3.81M

2028.89%1.92M

33.77%-755.00K

-133.95%-623.00K

471.58%543.00K

110.63%90.00K

73.81%-1.14M

2767.19%1.83M

121.11%95.00K

---847.00K

---4.35M

109.45%64.00K

-922.73%-450.00K

---677.00K

---44.00K

-Change in other current assets

----

---65.00K

--0.00

----

--0.00

-Change in other current liabilities

----

-100.00%0.00

--0.00

--2.00K

--0.00

Cash from non-recurring investing activities

Cash from operating activities

-6.70%-46.05M

-4.05%-38.11M

-8.02%-36.88M

-58.74%-57.61M

-12.83%-43.16M

-102.01%-36.63M

0.01%-34.14M

-17.05%-36.29M

25.00%-38.25M

27.43%-18.13M

37.19%-34.14M

-21.97%-31.01M

-132.78%-51.00M

-64.68%-24.98M

-415.15%-54.35M

-56.95%-25.42M

-1346.07%-21.91M

-60.78%-15.17M

-16.32%-10.55M

---16.20M

---1.52M

-93.80%-9.44M

-54.61%-9.07M

---4.87M

---5.87M

Investing cash flow

Net cash from continuing investing activities

----

--11.00K

--38.00K

----

--0.00

-100.00%0.00

--49.00K

--159.00K

--791.00K

--251.00K

----

--0.00

-120.00%-1.00K

0.00%4.00K

--5.00K

--4.00K

Capital expenditures

----

--11.00K

--38.00K

----

--0.00

-100.00%0.00

--49.00K

--159.00K

--882.00K

--251.00K

----

--0.00

----

0.00%4.00K

--5.00K

--4.00K

Net cash flow from disposal of fixed assets

----

--11.00K

--38.00K

----

--0.00

-100.00%0.00

--49.00K

--159.00K

--791.00K

--251.00K

----

--0.00

-120.00%-1.00K

0.00%4.00K

--5.00K

--4.00K

Net cash flow from business transactions

----

--0.00

-100.00%0.00

----

--0.00

--5.00M

--270.00M

----

--0.00

----

--0.00

Net cash flow from investment products

-11.93%32.41M

40.33%22.40M

239.22%67.43M

128.85%53.40M

184.08%36.80M

-68.98%15.96M

146.27%19.88M

-1622.43%-185.11M

-15.56%12.96M

285.02%51.47M

31.52%-42.96M

-60.59%12.16M

-55.80%15.34M

-75.38%-27.82M

-145.09%-62.73M

119.96%30.85M

125.20%34.71M

-238.67%-15.86M

-1221.27%-25.59M

---154.59M

---137.73M

132.33%11.44M

---1.94M

---35.38M

--0.00

Net cash flow from other investing activities

--0.00

----

Cash from non-current investing activities

Net cash flow from investing activities

-11.93%32.41M

40.26%22.39M

239.03%67.39M

128.85%53.40M

184.08%36.80M

-68.98%15.96M

146.27%19.88M

-1628.59%-185.11M

-14.67%12.96M

279.90%51.47M

25.91%-42.96M

-95.97%12.11M

-56.26%15.18M

-80.37%-28.61M

-126.54%-57.98M

294.61%300.85M

125.20%34.71M

-238.65%-15.86M

-1218.55%-25.59M

---154.59M

---137.73M

132.33%11.44M

-48425.00%-1.94M

---35.38M

---4.00K

Financing cash flow

Cash flow from continuous financing activities

--380.00K

-54.80%715.00K

-100.00%0.00

-99.86%373.00K

-100.00%0.00

537.90%1.58M

1083.04%1.32M

579.23%262.20M

-39.35%1.08M

100.75%248.00K

-92.14%112.00K

1817.64%38.60M

-49.48%1.79M

-1318.06%-32.91M

146.11%1.43M

118.09%2.01M

-98.66%3.54M

-97.84%2.70M

-51.99%579.00K

--923.00K

--264.58M

48.84%124.90M

2971.43%1.21M

--83.91M

---42.00K

Net cash flow from debt Issuance/repayment

----

--0.00

-100.00%0.00

--0.00

100.00%0.00

128.13%1.82M

--175.00K

--0.00

---800.00K

--800.00K

----

Net cash flow from common stock issuance/repurchase

----

--0.00

----

-100.00%0.00

578.23%261.57M

--1.08M

--248.00K

102.54%112.00K

776.30%38.57M

----

--0.00

---4.40M

--4.40M

-100.00%0.00

--0.00

--267.27M

-100.00%0.00

--0.00

--84.25M

--0.00

Net cash flow from preferred stock issuance/repurchase

----

--124.84M

----

Proceeds from stock option exercised by employees

--380.00K

-54.80%715.00K

-100.00%0.00

-91.56%373.00K

--0.00

--1.58M

--1.98M

12180.56%4.42M

----

102.27%36.00K

-102.27%-36.00K

-92.82%194.00K

906.22%5.83M

---1.59M

--1.59M

4725.00%2.70M

--579.00K

----

--56.00K

----

Net cash flow from other financing activities

--0.00

----

--0.00

100.00%0.00

--0.00

---2.69M

100.00%0.00

---336.00K

---42.00K

Net cash from non-recurrent financing activities

Net cash from financing activities

--380.00K

-54.80%715.00K

-100.00%0.00

-99.86%373.00K

-100.00%0.00

537.90%1.58M

1083.04%1.32M

579.23%262.20M

-39.35%1.08M

100.75%248.00K

-92.14%112.00K

1817.64%38.60M

-49.48%1.79M

-1318.06%-32.91M

146.11%1.43M

118.09%2.01M

-98.66%3.54M

-97.84%2.70M

-51.99%579.00K

--923.00K

--264.58M

48.84%124.90M

2971.43%1.21M

--83.91M

---42.00K

Net cash flow

Beginning cash balance

6.42%88.33M

1.22%103.33M

-36.69%72.82M

3.27%76.66M

-15.67%83.00M

57.42%102.08M

-18.90%115.02M

-39.22%74.23M

-36.96%98.43M

-73.28%64.85M

-59.88%141.83M

60.45%122.13M

161.24%156.15M

175.42%242.66M

185.89%353.56M

-74.07%76.12M

-64.46%59.77M

113.34%88.11M

142.00%123.67M

--293.54M

--168.20M

110.81%41.30M

100.38%51.10M

--19.59M

--25.50M

Current period cash flow changes

-108.68%-13.25M

21.37%-15.00M

335.89%30.52M

-109.40%-3.83M

73.77%-6.35M

-156.81%-19.08M

83.20%-12.94M

107.01%40.79M

28.86%-24.21M

138.83%33.59M

30.58%-76.99M

-92.90%19.71M

-308.17%-34.02M

-205.34%-86.50M

-211.84%-110.91M

263.33%277.44M

-86.96%16.34M

-122.33%-28.33M

-262.69%-35.56M

---169.87M

--125.34M

190.66%126.90M

-65.84%-9.81M

--43.66M

---5.91M

Ending cash balance

-2.05%75.08M

6.42%88.33M

1.22%103.33M

-36.69%72.82M

3.27%76.66M

-15.67%83.00M

57.42%102.08M

-18.90%115.02M

-39.22%74.23M

-36.96%98.43M

-73.28%64.85M

-59.88%141.83M

60.45%122.13M

161.24%156.15M

175.42%242.66M

185.89%353.56M

-74.07%76.12M

-64.46%59.77M

113.34%88.11M

--123.67M

--293.54M

165.93%168.20M

110.81%41.30M

--63.25M

--19.59M

Free cash flow

-6.70%-46.05M

-4.08%-38.12M

-8.13%-36.91M

-58.74%-57.61M

-12.83%-43.16M

-102.01%-36.63M

0.01%-34.14M

-16.86%-36.29M

25.23%-38.25M

29.90%-18.13M

37.48%-34.14M

-22.17%-31.05M

-133.50%-51.16M

-70.49%-25.86M

-417.52%-54.60M

-56.95%-25.42M

-1346.07%-21.91M

-60.78%-15.17M

-16.26%-10.55M

---16.20M

---1.52M

-93.60%-9.44M

-54.57%-9.07M

---4.87M

---5.87M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Cullinan Therapeutics Inc Generate?



Cullinan Therapeutics Inc generated -175.75M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Cullinan Therapeutics Inc's Operating Cash Flow Change Year Over Year?



Cullinan Therapeutics Inc's operating cash flow increased by -20.95% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Cullinan Therapeutics Inc Spend on Capital Expenditures?



Cullinan Therapeutics Inc spent 49.00K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Cullinan Therapeutics Inc's Financing Cash Flow Changed?



Cullinan Therapeutics Inc used 1.09M in financing activities in the latest quarter.

What is free cash flow and why does it matter for CGEM?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Cullinan Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -175.80M reflecting a -20.99% change from the previous year.